6,888 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Capula Management Ltd

Capula Management Ltd bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 6,888 shares of the biopharmaceutical company’s stock, valued at approximately $3,141,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $662,837,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after acquiring an additional 1,185,909 shares during the period. Holocene Advisors LP acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $194,616,000. AQR Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 295.2% in the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after acquiring an additional 555,759 shares during the last quarter. Finally, Orbis Allan Gray Ltd increased its position in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $313.41 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a 50 day moving average of $344.35 and a 200-day moving average of $409.75. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The firm has a market cap of $41.56 billion, a price-to-earnings ratio of 183.28 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the business earned ($0.65) earnings per share. The company’s revenue for the quarter was up 84.9% on a year-over-year basis. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,598 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the sale, the executive vice president directly owned 36,606 shares in the company, valued at approximately $11,993,955.90. This trade represents a 4.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 6,799 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the transaction, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at $32,315,464.20. This represents a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 53,923 shares of company stock valued at $18,072,087. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on ALNY. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Raymond James Financial restated an “outperform” rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Chardan Capital cut their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Truist Financial reduced their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.